|
See related Sutent cap information |
|
|
|
Manufacturer |
Pfizer |
|
Distributor |
Hong Kong: Zuellig/Macau: The Glory Medicina |
|
Contents |
Sunitinib malate |
|
Indications |
Treatment of GI stromal tumor after disease progression on or intolerance to imatinib mesylate; advanced renal cell carcinoma; progressive, well-differentiated pancreatic neuroendocrine tumor in patient w/ unresectable locally advanced or metastatic disease.
Click to view Sutent detailed prescribing infomation |
|
Dosage |
GI stromal tumor & renal cell carcinoma 50 mg daily over 4 wk, followed by a 2-wk off. Pancreatic neuroendocrine tumor 37.5 mg daily continuously w/o a scheduled off-treatment period. Max: 50 mg daily. Dose modification of 12.5-mg increment is based on individual safety & tolerability.
Click to view Sutent detailed prescribing infomation |
|
Overdosage |
View Sutent overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Special Precautions |
Baseline periodic monitoring of liver function tests, left ventricular ejection fraction & clinical signs & symptoms of CHF. Left ventricular dysfunction. QT interval prolongation, torsade de pointes, HTN, hemorrhagic events, thyroid dysfunction, impaired wound healing, adrenal insufficiency. Perform CBC w/ platelet count & serum chemistries including phosphate at the beginning of each treatment cycle. Pregnancy & lactation. Elderly. Childn.
Click to view Sutent detailed prescribing infomation |
|
Adverse Drug Reactions |
Fatigue, asthenia, fever, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspepsia, abdominal pain, constipation, HTN, peripheral edema, rash, hand-foot syndrome, skin discoloration, dry skin, hair color changes, altered taste, headache, back pain, arthralgia, pain in extremities, cough, dyspnea, anorexia & bleeding.
View ADR Monitoring Form |
|
Drug Interactions |
CYP3A4 inhibitors eg ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice; CYP3A4 inducers eg rifampin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarb, St. John's wort.
View more drug interactions with Sutent |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Description |
View Sutent description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Sutent mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Sutent capsule |
|
Sutent 12.5 mg x 28's |
 |
|
Sutent 50 mg x 28's |
 |
|
|
|
Manufacturer: |
Pfizer |
|
Distributor: |
Hong Kong: Zuellig
Macau: The Glory Medicina |
|
|
|
|
|
